ScreenerHero

BLRXBioLineRx Ltd.

NAS · US · Healthcare · Biotechnology · biolinerx.com
2.810USDMkt Cap: 12.27M $P/E: Infinity

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in gliobl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap12.27M $
Enterprise Value8.11M $
Revenue (TTM)1.40M $
Gross Profit950.00K $
Net Income (TTM)-1.18M $
Revenue/Share0.6000 USD
Last Price2.810 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS09071M2052
Valuation
P/E (Trailing)Infinity
P/E (Forward)-4.39
PEG—
EV/EBITDA-0.75
EV/Revenue5.78
P/S8.76
P/B0.78
EPS (TTM)0.00
EPS (Forward)-0.64
52W Range
2.8003% of range3.100
52W High3.100 USD
52W Low2.800 USD
Profitability
Gross Margin80.51%
Oper. Margin-629.77%
EBITDA Margin0.00%
Profit Margin-99.58%
ROE-6.46%
ROA-2.87%
Growth
Revenue Growth87.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.07M $
CapEx (TTM)27.00K $
FCF Margin-391.59%
FCF Yield-44.73%
Net Debt-8.28M $
Net Debt/EBITDA0.77
Balance Sheet
Debt/Equity0.56
Current Ratio1.58
Quick Ratio1.41
Book Value/Sh3.600 USD
Cash/Share3.988 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 15, 2019
Splits
Last Split1:40
Split DateJan 30, 2025
Analyst Consensus
Rating—
Target (Mean)23.00 USD
Upside (mean)+718.5%
Target Range23.00 USD – 23.00 USD
# Analysts1
Ownership
Shares Out.4.37M
Float4.16M
Insiders3.91%
Institutions1.52%
Short Interest
Short Ratio7.0d
Short % Float3.10%
Short % Out.3.10%
Shares Short134.84K
Short (prev mo.)136.65K
Technical
SMA 502.960 (-5.1%)
SMA 2002.932 (-4.1%)
Beta0.71
S&P 52W Chg19.18%
Avg Vol (30d)2.69K
Avg Vol (10d)8.20K
Technical Indicators
RSI (14)49.4
MACD-0.0375
MACD Signal-0.0611
MACD Hist.+0.0236
BB Upper2.898 USD
BB Middle2.760 USD
BB Lower2.621 USD
BB Width10.07%
ATR (14)0.2081 USD
Vol Ratio (20d)0.33x